angiotensin II receptor blocker + statin

A combination therapy of an angiotensin II receptor blocker (ARB) and a statin is used to target both hypertension and hypercholesterolemia, two major cardiovascular risk factors. ARBs act by selectively blocking the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced blood pressure. Statins inhibit HMG-CoA reductase, reducing cholesterol synthesis in the liver and lowering LDL cholesterol levels. Preclinical and clinical studies suggest that this combination may have synergistic effects beyond their individual actions, including improved vascular remodeling, reduced arterial inflammation, enhanced endothelial function, antioxidative effects against LDL oxidation, favorable macrophage polarization (toward M2 phenotype), increased skeletal muscle mass index in patients with cardiovascular disease (CVD), and potentially superior anti-atherosclerotic outcomes compared to monotherapy[1][2][4][5]. This dual approach addresses multiple aspects of cardiovascular risk management.

Other names

angiotensin Ⅱ receptor blocker + statinARB/statin combination